Stockreport

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia [Yahoo! Finance]

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF COBENFY has already been included in China's national-level schizophrenia treatment guidelines, underscoring the urgent need for new therapeutic options in China SHAN [Read more]